Table 1. Urinary 8-OHdG concentrations in study participants in the intervention trial.
| Urinary 8-OHdG (ng/mg creatinine) | ||||||
| Groups | No. of participants | Baseline | 1-month | 3-month | 6-month | P-values (Time)2 |
| Placebo | n = 37 | 64.5±42.7 | 65.8±48.5 | 68.3±48.1 | 73.5±51.0 | 0.133 |
| 58.0 (3.5–197.4) | 55.4 (3.0–241.6) | 66.5 (2.6–256.2) | 62.6 (4.9–258.2) | |||
| Placebo + TC | n = 37 | 64.1±23.6 | 45.6±25.43,4 | 40.6±20.23,4 | 37.8±17.73,4 | <0.001 |
| 65.1 (23.5–154.9) | 40.2 (9.6–132.6) | 37.2 (4.0–104.8) | 37.5 (8.9–93.6) | |||
| GTP | n = 39 | 84.6±74.3 | 48.2±44.63,4 | 38.7±37.83,4 | 33.5±33.13,4 | <0.001 |
| 65.4 (7.6–290.6) | 31.1 (2.5–175.1) | 25.0 (1.1–154.4) | 25.0 (0.5–164.5) | |||
| GTP + TC | n = 37 | 75.8±61.0 | 45.7±43.53,4 | 32.8±34.73,4 | 20.7±19.83,4 | <0.001 |
| 65.9 (4.2–249.8) | 33.2 (1.2–194.5) | 23.4 (0.5–167.2) | 16.7 (0.5–76.8) | |||
| P-values (Treatment)1 | 0.299 | 0.110 | <0.001 | <0.001 | ||
Urinary 8-OHdG values are expressed as Mean±SD, median (range).
1
P-values (Treatment) were from Kruskal-Wallis test of one-way ANOVA.
2
P-values (Time) were from Friedman’s test.
3
Significantly different from Placebo at the same time point, tested by Wilcoxon rank sum test with Bonferroni correction for multiple comparisons, P<0.050.
4
Significantly different from baseline in the same group, tested by Wilcoxon signed rank test with Bonferroni correction for multiple comparisons, P<0.001.